Julia Wolfe
#92,086
Most Influential Person Now
American composer
Julia Wolfe's AcademicInfluence.com Rankings
Download Badge
Communications
Why Is Julia Wolfe Influential?
(Suggest an Edit or Addition)According to Wikipedia, Julia Wolfe is an American composer and professor of music at New York University. According to The Wall Street Journal, Wolfe's music has "long inhabited a terrain of its own, a place where classical forms are recharged by the repetitive patterns of minimalism and the driving energy of rock". Her work Anthracite Fields, an oratorio for chorus and instruments, was awarded the 2015 Pulitzer Prize for Music. She has also received the Herb Alpert Award and was named a MacArthur Fellow .
Julia Wolfe's Published Works
Published Works
- Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. (2017) (258)
- Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma. (2019) (125)
- Phase I study of single agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL). (2016) (31)
- Single-Agent Ibrutinib in Recurrent/Refractory Central Nervous System Lymphoma (2016) (24)
- Mechanisms of Ischemic Stroke in Patients with Cancer: A Prospective Study (2021) (18)
- Phase II of Single-Agent Ibrutinib in Recurrent/Refractory Primary (PCNSL) and Secondary CNS Lymphoma (SCNSL) (2018) (13)
- Updated results of single-agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL). (2017) (11)
- Cancer-Related Ischemic Stroke Has a Distinct Blood mRNA Expression Profile. (2019) (9)
- Staging identifies non-CNS malignancies in a large cohort with newly diagnosed lymphomatous brain lesions (2019) (8)
- Phase I/II study of single agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL) (2016) (8)
- Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin. (2019) (4)
- Phase 1B of ibrutinib and high-dose methotrexate for recurrent/refractory CNS lymphoma. (2017) (3)
- ACTR-12. PHASE I/II STUDY OF SINGLE AGENT IBRUTINIB IN RECURRENT/REFRACTORY PRIMARY (PCNSL) AND SECONDARY CNS LYMPHOMA (SCNSL) (2016) (1)
- Dynamics of circulating tumor DNA in patients with advanced solid tumors treated with cediranib and olaparib. (2021) (0)
This paper list is powered by the following services:
Other Resources About Julia Wolfe
What Schools Are Affiliated With Julia Wolfe?
Julia Wolfe is affiliated with the following schools: